PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026International Journal of Pharmaceutics1 citations

ROS-responsive Prussian blue nanoplatform for synergistic myocardial ischemia/reperfusion injury therapy via EGCG delivery and DJ-1 pathway regulation

View Full Paper
JZJianan ZhangHainan General HospitalYHYangli HeYWYundi WuHainan University

Key Points

  • Improved myocardial ischemia/reperfusion injury outcomes highlight the efficacy of the novel nanoplatform.
  • The study demonstrated a significant reduction in injury markers through DJ-1 pathway regulation by the nanoplatform.
  • Assessment using a ROS-responsive Prussian Blue nanoplatform facilitated effective EGCG delivery for cardiac protection.
  • These findings may enable new therapeutic approaches for cardiac injury, but further clinical validation is needed.
Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/69a75d02c6e9836116a26643https://doi.org/10.1016/j.ijpharm.2026.126620
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Enhanced endometrial receptivity via epigallocatechin gallate (EGCG)-loaded menstrual blood-derived exosomes2025 · 2 citations
  2. 2A model of mitochondrial superoxide production during ischaemia-reperfusion injury for therapeutic development and mechanistic understanding2024 · 26 citations
  3. 3ROS-responsive hydrogel coating modified titanium promotes vascularization and osteointegration of bone defects by orchestrating immunomodulation2022 · 125 citations
  4. 4DJ-1: A promising therapeutic candidate for ischemia-reperfusion injury2021 · 35 citations
  5. 5Modulation of signaling pathways by DJ-1: An updated overview2022 · 68 citations